Login    Join free Add to favorites    中文
home > news > Merck Expands End-to-End Biodevelopment Centers in North America, China and Europe
Industry Updates | New Products | Supplier News | Upcoming Events | business | web
Merck Expands End-to-End Biodevelopment Centers in North America, China and Europe

hits:531     Date:01/11/17
Global expansion to meet strong market demand
Biodevelopment centers in Boston, Mass. and Shanghai, China feature full suite of Merck technologies and services
New process development centers and full single-use GMP facility in France to accelerate development of biologics
Darmstadt, Germany, January 10, 2017 鈥 Merck, a leading science and technology company, today announced the expansion of its end-to-end biodevelopment centers to meet increasing customer demand for its turnkey portfolio of bioprocessing products, manufacturing capabilities and industry leading technological expertise.  
The expansion, which includes the opening of two new process development centers in the U.S. and China, follows the commercial success of Merck鈥檚 biodevelopment center in Martillac, France. The two new units will be located in close proximity to customers in the Shanghai and Boston metropolitan areas. Each will provide a full range of process development capabilities and services. This includes cell line development services, both upstream and downstream process development, as well as non-GMP clinical production.  

鈥淲e are seeing an increasing global demand for end-to-end process development solutions and Merck offers a one-stop shop for biopharma customers,鈥 said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. 鈥淭his expansion reinforces our position as the premier supplier of all process development and clinical stage manufacturing solutions, materials and services needed for the production of biologics. This is a strategic, high-potential investment for Merck specifically designed to meet customer needs on three continents.鈥
Merck鈥檚 biodevelopment center in Martillac, France, is a fully operational single-use, GMP facility for manufacturing clinical stage batches. Equipped with a full suite of Merck technologies, including the 2000 liter single-use Mobius® bioreactor, Martillac offers biopharma companies a complete solution to support their clinical development programs.  
Merck鈥檚 end-to-end offering delivers important benefits and addresses key challenges for biopharmaceutical companies at all stages of molecule development and commercialization in any geography. In addition to the Mobius® bioreactor, the end-to-end portfolio includes solutions such as Lynx® CDR, Viresolve® Process Area Modules, Pellicon® and Centinel™ Intelligence Virus Defense.  
Early-stage companies with limited resources and infrastructure benefit from a partner with strong expertise and experience developing processes and GMP clinical manufacturing to help accelerate early clinical development programs. Companies in more advanced stages need to overcome the challenges of moving from late phase clinical development into commercial manufacturing, accelerating availability of affordable life-enhancing drugs. With an end-to-end approach, Merck can facilitate and accelerate scaling and technical transfer of an entire process to a new location.
About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life 鈥 from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of 鈧 12.85 billion in 66 countries.
Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Merck KGaA
Group Communications
External Communications
Frankfurter Str. 250
64293 Darmstadt
E-Mail: Media.Relations@merck.de
Mandatory Information can be found at www.merckgroup.com/mandatories
Hotline: +49 6151 72-5000
Related News>> more

Copyright(C) 2006-2018 Bio-Equip    E-mail:web@bio-equip.cn   娌狪CP澶06040519鍙